tepotinib

Overview

Tepotinib is a selective MET tyrosine kinase inhibitor approved for the treatment of NSCLC harboring MET exon 14 skipping mutations. MET exon 14 alterations are age-skewed, occurring at higher frequency in older patients. Tepotinib’s pivotal VISION trial enrolled patients across a broad age range.

Evidence in the corpus

• MET exon 14 skipping inhibitor; pivotal trial enrolled patients up to 74 years old; MET exon 14 skipping is rare in young-onset NSCLC (0.72% in patients ≤50 years vs 3.25% in patients >70 years), making tepotinib less relevant to the young-onset NSCLC population PMID:27346245

Resistance mechanisms

Cancer types (linked)

• NSCLC

Sources

This page was processed by crosslinker on 2026-05-14.